[Ip-health] Call for Action on Cancer Drugs by YP-CDN, KEI, and UAEM at 67th World Health Assembly

Thiru Balasubramaniam thiru at keionline.org
Mon May 19 16:20:01 PDT 2014

http://keionline.org/node/2011Call for Action on Cancer Drugs by YP-CDN,
KEI, and UAEM at 67th World Health Assembly
Submitted by Claire Cassedy <http://keionline.org/user/57723> on 19. May
2014 - 23:01

At the opening of the 67th World Health Assembly, today the Young
Professionals Chronic Disease Network (YP-CDN), Knowledge Ecology
International (KEI), and Universities Allied for Essential Medicines (UAEM)
released a briefing, "Cancer medicines are essential in reducing the global
burden of non-communicable diseases."

The briefing (attached) emphasized that although the WHA-endorsed 2013
Global Action Plan for the Prevention and Control of Non-communicable
Diseases (NCDs) set a laudable target of an "80% availability of the
affordable basic technologies and essential medicines, including generics,
required to treat major NCDs in both public and private facilities" by
2020, the international community must do more to ensure that medicines for
cancer are more widely accessible globally if they are to reach their
stated goal.

In addition, YP-CDN, KEI, and UAEM's briefing highlights the need for,

"...more attention to the promising and logical proposals to delink R&D
costs from product prices, and to provide incentives for treatments that
are affordable and feasible in low resource settings. Examples of
de-­linkage include the proposals for cancer prize fund alternatives to
patent monopolies, and the proposal for innovation inducement prizes to
stimulate innovation in open source low cost cancer diagnostics."

As the WHO works to reduce the global burden of NCDs, the global community
should recognize the failures of the current business model and consider
delinkage proposals that stimulate innovation in fields like oncology as
well as others.

Also discussed in the briefing are petitions filed in 2012 for two
anti-cancer drugs, imatinib and trastuzumab, to be added to the World
Health Organization's (WHO) Model Essential Medicines List (EML). Drugs
included on the WHO EML represent priority health care needs and play a
significant role in guiding nations' formularies and elevating these two
anti-cancer drugs would greatly increase visibility for and work towards
helping to reduce the burden of cancer globally.

YP-CDN, KEI, and UAEM support the WHO's proposed steps to consider the
inclusion of oncology products on the WHO EML, and in light of this fact,
calls the 67th WHA to action on several key considerations:

   - Monitor WHO's process for evaluating oncology medicines for inclusion
   in the EML, bearing in mind WHO's review of the WHO EML on cytotoxic and
   adjuvant medicines in relation to the 19th Expert Committee's consideration
   of the inclusion of imatinib and trastuzumab in 2015
   - Ensure that WHO guidelines for the treatment of breast, prostate, lung
   and colon cancers be issued by the 68th World Health Assembly in May 2015
   - Ensure that WHO's Prequalification Programme (WHO PQP) expand its
   remit to include the prequalification of oncology biopharmaceuticals,
   including such products as imatinib and trastuzumab.

For the full briefing, please see the attached file.


More information about the Ip-health mailing list